ONCOLYTICS BIOTECH-Wert mit Potential
| eröffnet am: | 10.02.13 00:51 von: | Heron |
| neuester Beitrag: | 24.04.21 23:58 von: | Ulrikesbyva |
| Anzahl Beiträge: | 236 | |
| Leser gesamt: | 53364 | |
| davon Heute: | 6 | |
bewertet mit 8 Sternen |
||
|
|
||
10.11.14 16:05
#51
CosmicTrade
Oncolytics - Surprise Unexpectedly?
http://www.nasdaq.com/symbol/oncy/real-time
‹(•¿-)›
http://www.nasdaq.com/symbol/oncy/real-time
‹(•¿-)›
10.11.14 19:14
#52
Lao-Tse
Gibt es Fragen?
Dieser Wert birgt seit Wochen Fantasie und der Ami rockt. Bin froh dabei sein zu können. Hab nur verpasst die erste Range mitzunehmen, aber dennoch fett im Plus. Geiler Wert. Oncy lets go on!
21.11.14 14:33
#53
CosmicTrade
Oncolytics Biotec low line reached?
Dieser Biowert schwappte einige Zeit um die 0,40€ herum,
komisch dass sich in D niemand dafür interessiert, man zockt doch
sonst weltmeisterlich in US Biowerten. Dabei unterscheidet sich
ONCY kaum von den scheinbar so populären Titeln wie Aeterna und anderen.
Hier ging es knapp unter 0,40$ (0,30€) danach zündete man eine Explosion auf $1,10.
zwischen zwei kleineren Anstiegen dümpelt ONCY nun um die $0,65 herum.
Es ist anzunehmen, dass das nicht mehr lange so bleiben wird.
http://charting.nasdaq.com/ext/...-03NA000000ONCY-&WD=539-HT=395-
Tieflinie: 0,40$ Kurs 21.11.2014: $0,67
komisch dass sich in D niemand dafür interessiert, man zockt doch
sonst weltmeisterlich in US Biowerten. Dabei unterscheidet sich
ONCY kaum von den scheinbar so populären Titeln wie Aeterna und anderen.
Hier ging es knapp unter 0,40$ (0,30€) danach zündete man eine Explosion auf $1,10.
zwischen zwei kleineren Anstiegen dümpelt ONCY nun um die $0,65 herum.
Es ist anzunehmen, dass das nicht mehr lange so bleiben wird.
http://charting.nasdaq.com/ext/...-03NA000000ONCY-&WD=539-HT=395-
Tieflinie: 0,40$ Kurs 21.11.2014: $0,67
21.11.14 17:58
#54
Lao-Tse
Danke
Darauf spekuliere ich...hab aber den ersten Bogen verpasst. Das Ding rockt noch. ;)
09.02.15 13:09
#56
Obelax
News
Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients
CALGARY, Feb. 9, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN® can infect a variety of brain tumors when delivered intravenously.
"High grade gliomas are typically a very aggressive form of cancer. They remain difficult to treat, particularly in pediatric patients, and are associated with poor survival outcomes," said Dr. Brad Thompson, President and CEO of Oncolytics. "While surgical resection, radiotherapy and chemotherapy may be treatment options, REOLYSIN® may offer these patients an alternative, more targeted therapeutic approach to treatment."
The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees. The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval. For more information, please visit: http://www.fda.gov/forindustry/...rareDiseasesConditions/default.htm.
According to the US Central Brain Tumor Registry an estimated 4,620 new cases of primary malignant and non-malignant brain and central nervous system tumors will be diagnosed in pediatric and adolescent patients in 2015. In patients between zero and 19 years old, the overall total incidence of HGG (including anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, mixed glioma, and malignant glioma) is approximately 0.8 per 100,000.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as, the Company's expectations related to the granting of Orphan Drug Designation for REOLYSIN®, the Company's belief as to the potential of REOLYSIN® as a cancer therapeutic, and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the tolerability of REOLYSIN® outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information: TMX Equicom: Nick Hurst, 300 5th Ave. SW, 10th Floor, Calgary, Alberta T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX Equicom: Michael Moore, San Diego, CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc.: Susan Forman, 335 West 38th Street, 3rd Floor, New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CALGARY, Feb. 9, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN® can infect a variety of brain tumors when delivered intravenously.
"High grade gliomas are typically a very aggressive form of cancer. They remain difficult to treat, particularly in pediatric patients, and are associated with poor survival outcomes," said Dr. Brad Thompson, President and CEO of Oncolytics. "While surgical resection, radiotherapy and chemotherapy may be treatment options, REOLYSIN® may offer these patients an alternative, more targeted therapeutic approach to treatment."
The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees. The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval. For more information, please visit: http://www.fda.gov/forindustry/...rareDiseasesConditions/default.htm.
According to the US Central Brain Tumor Registry an estimated 4,620 new cases of primary malignant and non-malignant brain and central nervous system tumors will be diagnosed in pediatric and adolescent patients in 2015. In patients between zero and 19 years old, the overall total incidence of HGG (including anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, mixed glioma, and malignant glioma) is approximately 0.8 per 100,000.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as, the Company's expectations related to the granting of Orphan Drug Designation for REOLYSIN®, the Company's belief as to the potential of REOLYSIN® as a cancer therapeutic, and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the tolerability of REOLYSIN® outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information: TMX Equicom: Nick Hurst, 300 5th Ave. SW, 10th Floor, Calgary, Alberta T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX Equicom: Michael Moore, San Diego, CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc.: Susan Forman, 335 West 38th Street, 3rd Floor, New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
17.02.15 14:12
#58
Fokka
Vorbörslich +11 %, läuft an ...
http://www.nasdaq.com/de/symbol/oncy/premarket
:-)
:-)
17.02.15 14:28
#59
Fokka
... und News !
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer
http://www.oncolyticsbiotech.com/news/...ncreatic-Cancer/default.aspx
http://www.oncolyticsbiotech.com/news/...ncreatic-Cancer/default.aspx
17.02.15 19:40
#61
Fokka
@Lao-Tse, geradezu wunderbar :-)
Bin mal gespannt wo die Reise hingeht.
Aber hier in Deutschland hat noch keiner was gemerkt.
Aber hier in Deutschland hat noch keiner was gemerkt.
18.02.15 13:07
#62
hAraldchef
News
Sind vorböslich wieder über 10% im Plus warn allerdings wie das bekannt wurd gleich plus 25%. Hoffen wir mal das Beste :)
http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#oncy
Lg
http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#oncy
Lg
18.02.15 14:31
#63
Fokka
Sieht wirklich gut aus ...
ich hoffe, evtl. Gewinnmitnahmen lassen noch ein wenig auf sich warten.
Mit einem leichten Rücksetzer muss man aber rechnen, es ist doch ein rasanter Anstieg.
Mit einem leichten Rücksetzer muss man aber rechnen, es ist doch ein rasanter Anstieg.
24.02.15 19:16
#65
Fokka
Hier ist, glaube ich, die Luft
erst mal raus.
Nur meine Meinung.
Bin jetzt "umgezogen" ...
:-)
Nur meine Meinung.
Bin jetzt "umgezogen" ...
:-)
25.02.15 13:52
#66
Lao-Tse
Bin ich auch...
Allerdings denke ich, dass sie um die 0,40 € wieder nach oben abprallt. Abwarten!
25.02.15 15:44
#67
hAraldchef
so
bin jetzt bei 0,6 rein, hab mich hier mal ein bisschen eingelesen und sieht alles nicht so schlecht aus meiner Meinung.....
25.02.15 23:22
#68
hAraldchef
nachbörslich :)
http://www.nasdaq.com/de/symbol/oncy/after-hours
11.03.15 21:19
#74
skate
was ist denn da blos los?
Alles steigt, sogar Morphosys, aber hier flüchten ein paar größere Anleger. Oder warten die auf den richtigen Einstieg?